443 related articles for article (PubMed ID: 14532122)
1. Redox regulation of PI 3-kinase signalling via inactivation of PTEN.
Leslie NR; Bennett D; Lindsay YE; Stewart H; Gray A; Downes CP
EMBO J; 2003 Oct; 22(20):5501-10. PubMed ID: 14532122
[TBL] [Abstract][Full Text] [Related]
2. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors.
Kwon J; Lee SR; Yang KS; Ahn Y; Kim YJ; Stadtman ER; Rhee SG
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16419-24. PubMed ID: 15534200
[TBL] [Abstract][Full Text] [Related]
3. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.
Leslie NR; Bennett D; Gray A; Pass I; Hoang-Xuan K; Downes CP
Biochem J; 2001 Jul; 357(Pt 2):427-35. PubMed ID: 11439092
[TBL] [Abstract][Full Text] [Related]
4. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein.
Paramio JM; Navarro M; Segrelles C; Gómez-Casero E; Jorcano JL
Oncogene; 1999 Dec; 18(52):7462-8. PubMed ID: 10602505
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
[TBL] [Abstract][Full Text] [Related]
6. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN.
Downes CP; Bennett D; McConnachie G; Leslie NR; Pass I; MacPhee C; Patel L; Gray A
Biochem Soc Trans; 2001 Nov; 29(Pt 6):846-51. PubMed ID: 11709086
[TBL] [Abstract][Full Text] [Related]
8. Acute regulation of the tumour suppressor phosphatase, PTEN, by anionic lipids and reactive oxygen species.
Downes CP; Walker S; McConnachie G; Lindsay Y; Batty IH; Leslie NR
Biochem Soc Trans; 2004 Apr; 32(Pt 2):338-42. PubMed ID: 15046604
[TBL] [Abstract][Full Text] [Related]
9. SHIP2 controls PtdIns(3,4,5)P(3) levels and PKB activity in response to oxidative stress.
Zhang J; Liu Z; Rasschaert J; Blero D; Deneubourg L; Schurmans S; Erneux C; Pesesse X
Cell Signal; 2007 Oct; 19(10):2194-200. PubMed ID: 17643961
[TBL] [Abstract][Full Text] [Related]
10. GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation.
Sternberger M; Schmiedeknecht A; Kretschmer A; Gebhardt F; Leenders F; Czauderna F; Von Carlowitz I; Engle M; Giese K; Beigelman L; Klippel A
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):131-43. PubMed ID: 12162696
[TBL] [Abstract][Full Text] [Related]
11. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.
Asano T; Yao Y; Zhu J; Li D; Abbruzzese JL; Reddy SA
Oncogene; 2004 Nov; 23(53):8571-80. PubMed ID: 15467756
[TBL] [Abstract][Full Text] [Related]
12. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene.
Li J; Simpson L; Takahashi M; Miliaresis C; Myers MP; Tonks N; Parsons R
Cancer Res; 1998 Dec; 58(24):5667-72. PubMed ID: 9865719
[TBL] [Abstract][Full Text] [Related]
13. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
15. Redox regulation of PTEN by S-nitrosothiols.
Yu CX; Li S; Whorton AR
Mol Pharmacol; 2005 Sep; 68(3):847-54. PubMed ID: 15967877
[TBL] [Abstract][Full Text] [Related]
16. PTEN: The down side of PI 3-kinase signalling.
Leslie NR; Downes CP
Cell Signal; 2002 Apr; 14(4):285-95. PubMed ID: 11858936
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression causes feedback upregulation of insulin receptor substrate 2.
Simpson L; Li J; Liaw D; Hennessy I; Oliner J; Christians F; Parsons R
Mol Cell Biol; 2001 Jun; 21(12):3947-58. PubMed ID: 11359902
[TBL] [Abstract][Full Text] [Related]
19. Metabolic switching of PI3K-dependent lipid signals.
Downes CP; Leslie NR; Batty IH; van der Kaay J
Biochem Soc Trans; 2007 Apr; 35(Pt 2):188-92. PubMed ID: 17371235
[TBL] [Abstract][Full Text] [Related]
20. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
